Hyperfine (HYPR) Stock Price, News & Analysis

Company Overview

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging (MRI) more accessible and convenient. Its flagship product, the Swoop Portable MR Imaging System, is designed to provide brain imaging at or near the patient’s bedside rather than requiring transport to a traditional MRI suite.

The Swoop system uses a low-field magnetic resonance platform, artificial intelligence-enabled image processing and a mobile design to support neuroimaging in settings such as hospitals, intensive care units and other clinical environments. The company’s technology is intended to help clinicians evaluate conditions including stroke, brain injury and other neurological disorders when conventional MRI access may be limited or patient transport may present challenges.

Hyperfine was founded in 2014 and is headquartered in Guilford, Connecticut. Its products have been developed for healthcare providers in the United States and international markets, subject to applicable regulatory clearances and approvals. The company became publicly traded on the Nasdaq following a business combination completed in 2021.

Key Stats

• Today's Range: $0.76 to $0.81
• 50-Day Range: $0.77 to $0.98
• 52-Week Range: $0.75 to $1.94
• Volume: 420,449 shs
• Average Volume: 743,844 shs
• Market Capitalization: $80.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.03
• Consensus Rating: Hold

Hyperfine Stock Analysis - MarketRank™

Hyperfine scored higher than 60% of companies evaluated by MarketBeat, and ranked 364th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Hyperfine has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Hyperfine has a consensus price target of $2.03, representing about 158.0% upside from its current price of $0.79.

Amount of Analyst Coverage

Hyperfine has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperfine is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperfine is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hyperfine has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.99% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 8.46.

Change versus previous month

Short interest in Hyperfine has recently decreased by 7.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperfine does not currently pay a dividend.

Dividend Growth

Hyperfine does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.50

News Sentiment

Hyperfine has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Hyperfine this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Hyperfine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hyperfine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,486.00 in company stock.

Percentage Held by Insiders

26.33% of the stock of Hyperfine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.03% of the stock of Hyperfine is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Confirmed): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:HYPR
• CIK: 1833769
• Web: hyperfine.io
• Phone: 866-796-6767
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hyperfine: $2.03
• High Price Target: $2.50
• Low Price Target: $1.60
• Potential Upside/Downside: +167.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.57 million
• Net Margins: -210.75%
• Pretax Margin: -210.75%
• Return on Equity: -97.88%
• Return on Assets: -61.81%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 6.15
• Quick Ratio: 5.45

Sales & Book Value

• Annual Sales: $11.40 million
• Price / Sales: 7.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 1.81

Miscellaneous

• Outstanding Shares: 106,050,000
• Free Float: 78,126,000
• Market Cap: $80.70 million
• Optionable: Optionable
• Beta: 1.45